Study of cladribine+venetoclax after failure of venetoclax+hypomethylating agent in monocytic AML

Primary Objective

To assess the efficacy of cladribine+venetoclax (Clad/Ven) in AML with a monocytic phenotype that is relapsed after or refractory to HMA/Ven

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Christine McMahon

Christine McMahon

Study ID

Protocol Number: 23-0273

More information available at ClinicalTrials.gov: NCT06232655

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers